ULTRAGRIS-165 Drug Patent Profile
✉ Email this page to a colleague
When do Ultragris-165 patents expire, and what generic alternatives are available?
Ultragris-165 is a drug marketed by Pliva and is included in one NDA.
The generic ingredient in ULTRAGRIS-165 is griseofulvin, ultramicrocrystalline. There is one drug master file entry for this compound. Additional details are available on the griseofulvin, ultramicrocrystalline profile page.
Summary for ULTRAGRIS-165
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 96 |
Patent Applications: | 4,434 |
DailyMed Link: | ULTRAGRIS-165 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ULTRAGRIS-165
US Patents and Regulatory Information for ULTRAGRIS-165
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pliva | ULTRAGRIS-165 | griseofulvin, ultramicrocrystalline | TABLET;ORAL | 062645-001 | Jun 30, 1992 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |